Observational studyAdvances in therapy2025

A Time and Motion Study Comparing Subcutaneous Pembrolizumab Versus Intravenous Pembrolizumab in Combination with Chemotherapy for the Treatment of Metastatic Non-small Cell Lung Cancer.

Erwin De Cock et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.